Long-Term Outcomes of Patients with Poor Prognostic Factors Following Transanal Endoscopic Microsurgery (TEMS) for Early Rectal Cancer

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2025 Feb 26

PMID 40002934

Authors

Muneeb Ul Haq

Khaled Noureldin

David Mark Pritchard

Arthur Sun Myint

Carrie A Duckworth

Ngu Wah Than

David M Hughes

Shakil Ahmed

Muhammad Ahsan Javed

Affiliations

Soon will be listed here.

Abstract

Transanal endoscopic microsurgery (TEMS) is an organ-preserving approach for treatment of early rectal cancer (ERC). However, adverse histopathological features identified post-TEMS often necessitate adjuvant therapy. This study aims to compare the long-term oncological outcomes of patients who underwent TEMS and were offered adjuvant treatments with total mesorectal excision (TME), chemoradiotherapy (CRT), radiotherapy (RT), active surveillance, or dose escalation with contact X-ray brachytherapy (CXB). This study included patients treated with TEMS for ERC between September 2012 and December 2022, with follow-up until December 2023. Patients with adverse histopathological features (extra-mural venous invasion, lympho-vascular invasion, R1 margins, tumour budding) were assigned to adjuvant treatments. Inverse probability of treatment weighting (IPTW) was applied to mitigate selection bias. Of the 117 patients, 24 underwent TME, 17 received CRT, 25 received RT, 14 underwent active surveillance, and 37 patients received CXB boost along with CRT. The median follow-up was 60 months (IQR 52-73). During this time, 29 patients developed recurrence, and 15 died. The 5-year overall survival (OS) was 78.6%, and disease-free survival (DFS) was 70.9%. Compared to CXB, the mortality risk for CRT (HR = 0.81; 95% CI: 0.20-3.28; = 0.77) and TME (HR = 3.68; 95% CI: 0.46-29.79; = 0.22) was not significantly different. However, TME was associated with a significantly higher recurrence risk compared to CXB (HR = 7.57; 95% CI: 1.23-46.84; = 0.029). An organ-preserving strategy with CRT or CRT combined with a CXB boost may offer comparable long-term outcomes and reduced recurrence risks for patients undergoing TEMS for ERC with poor prognostic features. Further research with larger cohorts is needed to validate these results.

References

Paty P, Nash G, Baron P, Zakowski M, Minsky B, Blumberg D . Long-term results of local excision for rectal cancer. Ann Surg. 2002; 236(4):522-29; discussion 529-30. PMC: 1422607. DOI: 10.1097/00000658-200210000-00015. View

Javed M, Shamim S, Slawik S, Andrews T, Montazeri A, Ahmed S . Long-term outcomes of patients with poor prognostic factors following transanal endoscopic microsurgery for early rectal cancer. Colorectal Dis. 2021; 23(8):1953-1960. DOI: 10.1111/codi.15693. View

Peng H, Liao Z, Lin X, Qiu X, You K . Definitive radiotherapy or chemoradiotherapy for distal rectal cancer with early stage of cT1-2N0. Cancer Manag Res. 2019; 11:5221-5229. PMC: 6578584. DOI: 10.2147/CMAR.S198113. View

Balyasnikova S, Read J, Tait D, Wotherspoon A, Swift I, Cunningham D . The results of local excision with or without postoperative adjuvant chemoradiotherapy for early rectal cancer among patients choosing to avoid radical surgery. Colorectal Dis. 2016; 19(2):139-147. DOI: 10.1111/codi.13477. View

Morino M, Risio M, Bach S, Beets-Tan R, Bujko K, Panis Y . Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surg Endosc. 2015; 29(4):755-73. DOI: 10.1007/s00464-015-4067-3. View

Wan L, Sun Z, Peng W, Wang S, Li J, Zhao Q . Selecting Candidates for Organ-Preserving Strategies After Neoadjuvant Chemoradiotherapy for Rectal Cancer: Development and Validation of a Model Integrating MRI Radiomics and Pathomics. J Magn Reson Imaging. 2022; 56(4):1130-1142. DOI: 10.1002/jmri.28108. View

Slater A, Betts M, Anderson E, Cunningham C . Transanal endoscopic microsurgery for rectal cancer. Clin Radiol. 2015; 71(2):e121-9. DOI: 10.1016/j.crad.2015.10.022. View

Hompes R, McDonald R, Buskens C, Lindsey I, Armitage N, Hill J . Completion surgery following transanal endoscopic microsurgery: assessment of quality and short- and long-term outcome. Colorectal Dis. 2014; 15(10):e576-81. DOI: 10.1111/codi.12381. View

Herzog T, Belyaev O, Chromik A, Weyhe D, Mueller C, Munding J . TME quality in rectal cancer surgery. Eur J Med Res. 2010; 15:292-6. PMC: 3351953. DOI: 10.1186/2047-783x-15-7-292. View

10.

Komen N, Dewint P, Van den Broeck S, Pauli S, De Schepper H . Rectal cancer surgery : what's in a name?. Acta Gastroenterol Belg. 2019; 82(1):67-74. View

11.

Myint A, Smith F, Gollins S, Wong H, Rao C, Whitmarsh K . Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation?. Br J Radiol. 2017; 90(1080):20170175. PMC: 6047662. DOI: 10.1259/bjr.20170175. View

12.

Dhadda A, Myint A, Thamphya B, Hunter I, Hershman M, Gerard J . A multi-centre analysis of adjuvant contact X-ray brachytherapy (CXB) in rectal cancer patients treated with local excision - Preliminary results of the CONTEM1 study. Radiother Oncol. 2021; 162:195-201. DOI: 10.1016/j.radonc.2021.07.021. View

13.

Hossain M, Karuniawati H, Jairoun A, Urbi Z, Ooi D, John A . Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers (Basel). 2022; 14(7). PMC: 8996939. DOI: 10.3390/cancers14071732. View

14.

Rutter M, East J, Rees C, Cripps N, Docherty J, Dolwani S . British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. Gut. 2019; 69(2):201-223. PMC: 6984062. DOI: 10.1136/gutjnl-2019-319858. View

15.

Wang X, Chi P, Zhang Y, Lin H, Lu X, Huang Y . Survival outcome of adjuvant radiotherapy after local excision for T2 early rectal cancer: An analysis based on the surveillance, epidemiology, and end result registry database. Eur J Surg Oncol. 2018; 44(12):1865-1872. DOI: 10.1016/j.ejso.2018.08.024. View

16.

Allaix M, Arezzo A, Morino M . Transanal endoscopic microsurgery for rectal cancer: T1 and beyond? An evidence-based review. Surg Endosc. 2016; 30(11):4841-4852. DOI: 10.1007/s00464-016-4818-9. View

17.

Morino M, Allaix M, Arolfo S, Arezzo A . Previous transanal endoscopic microsurgery for rectal cancer represents a risk factor for an increased abdominoperineal resection rate. Surg Endosc. 2013; 27(9):3315-21. DOI: 10.1007/s00464-013-2911-x. View

18.

Sasaki T, Ito Y, Ohue M, Kanemitsu Y, Kobatake T, Ito M . Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase II Clinical Trial. Dis Colon Rectum. 2017; 60(9):914-921. PMC: 5553237. DOI: 10.1097/DCR.0000000000000870. View

19.

Xue X, Lin G . Transanal endoscopic microsurgery: exploring its indications and novel applications. A narrative review. Wideochir Inne Tech Maloinwazyjne. 2022; 17(1):95-103. PMC: 8886471. DOI: 10.5114/wiitm.2021.108811. View

20.

Choi M, Huh J, Shin J, Park Y, Cho Y, Kim H . Prognostic Factors and Treatment of Recurrence after Local Excision of Rectal Cancer. Yonsei Med J. 2021; 62(12):1107-1116. PMC: 8612863. DOI: 10.3349/ymj.2021.62.12.1107. View